SEGMENT INFORMATION

3 Months Ended

Dec. 31, 2023

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE H – SEGMENT INFORMATION

As detailed in Note B above, the Company has three reportable segments; (1) Therapeutic DNA Production Services, (2) MDx Testing Services, and (3) DNA Tagging and Security Products and Services. Resources are allocated by our CEO, COO CFO and CLO whom, collectively the Company has determined to be our CODM.

Information regarding operations by segment for the three-month period ended December 31, 2023 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services and Kits		Security Products		Consolidated
Revenues
Product revenues	$	—	$	—	$	307,317	$	307,317
Service revenues		77,535		—		169,612		247,147
Clinical laboratory service revenues		—		342,740		—		342,740
Less intersegment revenues		—		(6,040)		—		(6,040)
Total revenues	$	77,535	$	336,700	$	476,929	$	891,164
Gross profit	$	77,535	$	(62,958)	$	216,520	$	231,097
(Loss) from segment operations (a)	$	(1,259,046)	$	(496,512)	$	(784,303)	$	(2,539,861)

NOTE H – SEGMENT INFORMATION, continued

Information regarding operations by segment for the three-month period ended December 31, 2022 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	127,506	$	—	$	388,890	$	516,396
Service revenues		121,743		—		110,318		232,061
Clinical laboratory service revenues		—		4,565,815		—		4,565,815
Less intersegment revenues		—		(51,520)		—		(51,520)
Total revenues	$	249,249	$	4,514,295	$	499,208	$	5,262,752
Gross profit	$	170,924	$	1,933,219	$	273,540	$	2,377,683
(Loss) income from segment operations (a)	$	(852,253)	$	1,109,884	$	(474,715)	$	(217,084)

Reconciliation of segment loss from operations to consolidated loss before provision for income taxes is as follows:

	December 31,
	2023		2022
Loss from operations of reportable segments	$	(2,539,861)	$	(217,084)
General corporate expenses (b)		(1,249,205)		(1,001,894)
Interest income		33,323		3,686
Unrealized gain (loss) on change in fair value of warrants classified as a liability		2,639,000		(2,637,800)
Other (expense) income, net		(13,538)		8,846
Consolidated loss before provision for income taxes	$	(1,130,281)	$	(3,844,246)

(a) Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b) General corporate expenses consist of Selling, general and administrative expenses that are not specifically identifiable to a segment.